These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35060816)

  • 1. Tocilizumab and Aflibercept as a Treatment Option for Refractory Macular Edema after Acute Retinal Necrosis.
    Bograd A; Villiger PM; Munk MR; Bolt I; Tappeiner C
    Ocul Immunol Inflamm; 2023 Jan; 31(1):242-245. PubMed ID: 35060816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept in the management of acute retinal necrosis syndrome-related macular edema.
    Ortega-Evangelio L; Navarrete-Sanchis J; Williams BK; Tomás-Torrent JM
    Eur J Ophthalmol; 2018 Mar; 28(2):259-261. PubMed ID: 28967076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
    Ozkaya A; Demir G; Kirmaci A
    Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion.
    Hogg HJ; Di Simplicio S; Pearce MS
    Eur J Ophthalmol; 2021 Mar; 31(2):548-555. PubMed ID: 32009462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
    Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
    Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between the patterns of diabetic macular edema and photoreceptors' response after intravitreal ranibizumab treatment: a spectral-domain optical coherence tomography study.
    Chatziralli I; Theodossiadis G; Dimitriou E; Kazantzis D; Theodossiadis P
    Int Ophthalmol; 2020 Oct; 40(10):2441-2448. PubMed ID: 32424527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential Sterile Intraocular Inflammation Associated With Consecutive Intravitreal Injections of Aflibercept and Ranibizumab.
    Grewal DS; Schwartz T; Fekrat S
    Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):428-431. PubMed ID: 28499055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Acute Retinal Necrosis after Intravitreal Ranibizumab for Exudative Macular Degeneration.
    Pan Y; Huang X; Wu Z; Lu S; Chen T; Zou W
    Optom Vis Sci; 2021 Mar; 98(3):206-211. PubMed ID: 33633018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
    Nawar AE; Wasfy T; Shafik HM
    BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
    Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
    J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results.
    Türkseven Kumral E; Erçalık NY
    Semin Ophthalmol; 2021 Nov; 36(8):723-727. PubMed ID: 33760698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
    Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.